Every 424B that Annovis Bio, Inc. (ANVS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ANVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANVS filings page.
Annovis Bio, Inc. is conducting a registered offering of 7,895,000 shares of common stock, each sold with nine-tenths of a warrant, at a combined public offering price of $1.90 per share and accompanying warrant.
The offering includes warrants to purchase up to 7,105,500 shares with a six-year term and a $2.25 exercise price; delivery is expected on or about May 21, 2026. The company estimates net proceeds of approximately $13.8M (assuming no warrant exercises) and states cash and cash equivalents of $14.2M as of March 31, 2026, which it believes funds operations into the fourth quarter of 2026. The prospectus supplement also discloses existing outstanding warrants, stock options and reserved shares that could dilute holders if exercised.
Annovis Bio is offering common stock together with detachable warrants pursuant to this prospectus supplement to its Form S-3 shelf registration. The supplement discloses underwriting arrangements with Canaccord and reiterates that the exact number of shares offered in this supplement is presented in the prospectus language but left blank in the excerpt.
The company reported $14.2M cash as of March 31, 2026, an accumulated deficit of $181.3M, and 34,646,868 shares outstanding as of May 15, 2026. Recent financing included a registered direct sale of 5,263,156 shares and accompanying warrants at $1.90 per unit, generating net proceeds of $9.3M.
Annovis Bio, Inc. is conducting a registered direct offering of 5,263,156 shares of common stock paired with warrants to purchase up to 5,263,156 additional shares. Each share is sold together with a warrant at a combined public offering price of $1.90 per pair.
The warrants will be first exercisable six months after issuance, expire five and one-half years from issuance, and have an exercise price of $2.50 per share. The company expects net proceeds of approximately $9.175 million, which it plans to use to continue Phase 3 development of buntanetap for Alzheimer’s disease and for working capital and general corporate purposes. Shares outstanding were 29,269,237 as of April 8, 2026, and the expected post-offering outstanding share count is 34,532,393 assuming full sale of this offering.